Designing CAR-T cell therapy for clear cell renal cell carcinoma: preclinical evaluation using cell sorting and single cell sequencing
29 Jun 2022
Chimeric antigen receptor (CAR)-T cell therapy is a new type of “living drug” that has proven to be a powerful immunotherapy for hematologic malignancies. However, this success has not yet been transferred to solid tumors due to inefficient homing of CAR-T cells, the immunosuppressive tumor microenvironment (TME), and on-target off-tumor toxicities due to the shared epitopes on healthy tissues. The tumor associated antigen carbonic anhydrase IX (CA-IX) is overexpressed on clear cell renal cell carcinomas (ccRCC) and many other solid tumors.
Join this webinar to learn how engineered anti–CA-IX targeted CAR-T cells secreting human anti-programmed death ligand 1 (PDL-1) antibodies at the tumor site restore active anti-tumor immunity. An elevated expression of pro-inflammatory genes, downregulation of inhibitory immune modulator genes, and less regulatory T-cell differentiation of 4-1BB are observed during the CAR-T mediated response. In addition, anti–PDL-1 secreting CAR-T cells exhibit superior efficacy and less exhaustion and reverse the TME.
Key learning objectives
- Learn how engineered CAR-T cells are purified using the microfluidics chip based MA900 cell sorter for downstream functional assays.
- Review the workflow for evaluating the efficacy and long-term persistence of CAR-T cells in preclinical studies and for profiling enriched tumor infiltrating lymphocytes using single cell RNA sequencing.
- Understand how ex vivo engineered T cells represent an innovative approach to achieving a durable, long term, complete response against solid tumors.
Who should attend?
- This webinar will provide insights to researchers who want to learn how CAR-T cells secreting PDL-1 antibodies can be engineered for targeting solid tumors such as ccRCC.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.